Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease

Alkhatatbeh,Mohammad J.; Lincz,Lisa  F.; Thorne,Rick  F.

doi:10.3892/etm.2016.3069

Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease

Authors:
- Mohammad J. Alkhatatbeh
- Lisa F. Lincz
- Rick F. Thorne
View Affiliations

Affiliations: Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan, Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia, School of Environmental and Life Sciences, University of Newcastle, Ourimbah, NSW 2258, Australia
Published online on: February 10, 2016 https://doi.org/10.3892/etm.2016.3069
Pages: 1487-1492

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an inflammatory condition caused by hepatic lipid accumulation that is associated with insulin resistance, diabetes and metabolic syndrome. Although statins should be used with caution in liver diseases, they are increasingly investigated as a possible treatment for NAFLD. The present study recreated an in vitro model of NAFLD using HepG2 cells exposed to oleic acid (OA), which was used to quantify OA-induced lipid accumulation in HepG2 cells treated with various concentrations of simvastatin. In addition, the effect of simvastatin on HepG2 cell morphology and microparticle generation as a marker of cell apoptosis was assessed. OA‑induced lipid accumulation was quantified by Oil Red O staining and extraction for optical density determination. Stained lipid droplets were visualized using phase contrast microscopy. Furthermore, HepG2 cell‑derived microparticles were counted by flow cytometry subsequent to staining for Annexin V. HepG2 cells treated with 0‑1 mM OA showed dose‑dependent lipid accumulation. Treatment of HepG2 cells with increasing concentrations of simvastatin followed by treatment with 1 mM OA showed that low simvastatin concentrations (4‑10 µM) were able to reduce lipid accumulation by ~40%, whereas high simvastatin concentrations (20 and 30 µM) induced apoptotic changes in cell morphology and increased the production of Annexin V+ microparticles. This suggests that low simvastatin doses may have a role in preventing NAFLD. However, further investigations are required to confirm this action in vivo and to determine the underlying mechanism by which simvastatin reduces hepatic steatosis.

View Figures

View References

1	Green CJ and Hodson L: The influence of dietary fat on liver fat accumulation. Nutrients. 6:5018–5033. 2014. View Article : Google Scholar : PubMed/NCBI
2	Baraona E and Lieber CS: Effects of ethanol on lipid metabolism. J Lipid Res. 20:289–315. 1979.PubMed/NCBI
3	Souza MR, Diniz Mde F, Medeiros-Filho JE and Araújo MS: Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 49:89–96. 2012. View Article : Google Scholar : PubMed/NCBI
4	Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 107:450–455. 1999. View Article : Google Scholar : PubMed/NCBI
5	Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T and Ratziu V: Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 35:23–28. 2011. View Article : Google Scholar : PubMed/NCBI
6	Onnerhag K, Nilsson PM and Lindgren S: Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol. 49:1111–1118. 2014. View Article : Google Scholar : PubMed/NCBI
7	Centis E, Marzocchi R, Suppini A, Dalle Grave R, Villanova N, Hickman IJ and Marchesini G: The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des. 19:5270–5279. 2013. View Article : Google Scholar : PubMed/NCBI
8	Angelico F, Burattin M, Alessandri C, Del Ben M and Lirussi F: Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev. CD0051662007.PubMed/NCBI
9	Tolman KG and Dalpiaz AS: Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag. 3:1153–1163. 2007.PubMed/NCBI
10	Basaranoglu M, Acbay O and Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 31:3841999. View Article : Google Scholar : PubMed/NCBI
11	Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M and Chayama K: Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 57:1711–1728. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O and Memik F: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 17:713–718. 2003. View Article : Google Scholar : PubMed/NCBI
13	Calderon RM, Cubeddu LX, Goldberg RB and Schiff ER: Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: A therapeutic dilemma. Mayo Clin Proc. 85:349–356. 2010. View Article : Google Scholar : PubMed/NCBI
14	Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S and Aramin H: Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 12:CD0086232013.PubMed/NCBI
15	Egan M and Prasad S: PURLs: Statins for patients with nonalcoholic fatty liver? J Fam Pract. 60:536–538. 2011.PubMed/NCBI
16	Nseir W and Mahamid M: Statins in nonalcoholic fatty liver disease and steatohepatitis: Updated review. Curr Atheroscler Rep. 15:3052013. View Article : Google Scholar : PubMed/NCBI
17	Dima A, Marinescu AG and Dima AC: Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med. 50:19–25. 2012.PubMed/NCBI
18	Cui W, Chen SL and Hu KQ: Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res. 2:95–104. 2010.PubMed/NCBI
19	Liu JF, Ma Y, Wang Y, Du ZY, Shen JK and Peng HL: Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother Res. 25:588–596. 2011. View Article : Google Scholar : PubMed/NCBI
20	Susztak K, Ciccone E, McCue P, Sharma K and Böttinger EP: Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2:e452005. View Article : Google Scholar : PubMed/NCBI
21	Rossi J, Rouleau L, Tardif JC and Leask RL: Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress. Life Sci. 87:92–99. 2010. View Article : Google Scholar : PubMed/NCBI
22	Alkhatatbeh MJ, Enjeti AK, Acharya S, Thorne RF and Lincz LF: The origin of circulating CD36 in type 2 diabetes. Nutr Diabetes. 3:e592013. View Article : Google Scholar : PubMed/NCBI
23	Robert S, Poncelet P, Lacroix R, Arnaud L, Giraudo L, Hauchard A, Sampol J and Dignat-George F: Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: A first step towards multicenter studies? J Thromb Haemost. 7:190–197. 2009. View Article : Google Scholar : PubMed/NCBI
24	Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS and Dignat-George F: ISTH SSC Workshop: Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: Results of the International Society on Thrombosis and Haemostasis SSC collaborative workshop. J Thromb Haemost. 8:2571–2574. 2010. View Article : Google Scholar : PubMed/NCBI
25	Hargett LA and Bauer NN: On the origin of microparticles: From platelet dust to mediators of intercellular communication. Pulm Circ. 3:329–340. 2013. View Article : Google Scholar : PubMed/NCBI
26	Gomez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV and O'Connor JE: A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 165:106–116. 2007. View Article : Google Scholar : PubMed/NCBI
27	de Keyser CE, Koehler EM, Schouten JN, Visser LE, Hofman A, Janssen HL and Stricker BH: Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Dig Liver Dis. 46:720–725. 2014. View Article : Google Scholar : PubMed/NCBI
28	Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1569–1582. 1992.PubMed/NCBI
29	Liao JK and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
30	Stein EA, Lane M and Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:66B–69B. 1998. View Article : Google Scholar : PubMed/NCBI
31	Huang X, Ma J, Xu J, Su Q and Zhao J: Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Mol Med Rep. 11:2334–2340. 2015.PubMed/NCBI
32	Kah J, Wüstenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G and Sass G: Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 28:1077–1083. 2012.PubMed/NCBI
33	Relja B, Meder F, Wilhelm K, Henrich D, Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI